The effects of kininase II inhibition by SQ 14225 on kidney kallikrein-kinin and prostaglandin systems in conscious dogs.
The novel kininase II inhibitor SQ 14225 was intravenously administered to normal conscious dogs at the dose of 0.1 mg/kg. Urine kinin excretion increased from 14 +/- 6 ng/h to 163 +/- 18 ng/h. Separation by column chromatography showed that the increased urine kinin excretion was due to increased excretion of bradykinin. The enhanced urinary kinin excretion was associated by increased sodium (70%) and decreased kallikrein (27%) excretion. Urine volume and urinary prostaglandin excretion were not significantly affected by SQ 14225 treatment.
D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D002852:Chromatography, Ion Exchange; D004285:Dogs; D005260:Female; D007610:Kallikreins / Q000652:urine*; D007668:Kidney / Q000378:metabolism*; D007705:Kinins / Q000652:urine*; D011392:Proline / Q000031:analogs & derivatives* / Q000494:pharmacology; D011453:Prostaglandins / Q000652:urine*; D011458:Prostaglandins E / Q000652:urine; D012964:Sodium / Q000652:urine
D000806:Angiotensin-Converting Enzyme Inhibitors; D007705:Kinins; D011453:Prostaglandins; D011458:Prostaglandins E; D011392:Proline; D012964:Sodium; D007610:Kallikreins